Supporting direct access to diagnostic imaging for cancer diagnostics
The Essentials of Diagnostics: Introduction to Molecular Diagnostics … · 2016-08-14 · Making...
Transcript of The Essentials of Diagnostics: Introduction to Molecular Diagnostics … · 2016-08-14 · Making...
1 Making Diagnostics Matter Making Diagnostics Matter
The Essentials of Diagnostics:
Introduction to Molecular Diagnostics
Webinar
July 9, 2013 12 Noon
2 Making Diagnostics Matter Making Diagnostics Matter
DxInsights’ mission is
to educate healthcare
stakeholders on the
power and value of
diagnostics and their
impact on improving
patient outcomes and
reducing costs
3 Making Diagnostics Matter Making Diagnostics Matter
DxInsights is an industry-wide educational organization connecting stakeholders to the best
diagnostic resources and to each other.
Web-based
Resource
Center
Medical
School
Curriculum
Educational
Events
Original
Research and
Collaboration
Technology &
Regulation
Global
Payment
Public
Affairs Legal
Medical
Technology
Learning
Institute
Government
Affairs
AdvaMedDx is a diagnostics “association within an association” at
AdvaMed, representing about 70 global diagnostics manufacturers.
Vision
AdvaMedDx will be a world leader in advocating for the power of medical diagnostics to promote wellness, improve patient outcomes and advance public health.
Goals
• Create an understanding of the value of medical diagnostic tests. • Be a valued contributor to diagnostics and health care policy. • Ensure timely patient access to safe and effective diagnostic tests. • Modernize payment systems for diagnostic tests.
Advocacy & Public Affairs
Create a core group of policy makers who understand diagnostics and key policy needs.
Form and strengthen stakeholder alliances.
Develop policy and educational content; establish communications channels.
Expand global collaboration.
AdvaMedDx.org
6 Making Diagnostics Matter Making Diagnostics Matter
The Essentials of Diagnostics: Introduction to Molecular Diagnostics DxInsights and AdvaMedDx Present:
7 Making Diagnostics Matter Making Diagnostics Matter
Diagnostic tests are the foundation of a successful health care system,
providing critical information that healthcare providers and patients need to
make the right medical decisions.
Molecular diagnostics is a dynamic and transformative area of diagnostics,
leading to insights in research and treatment in many disease states that
are revolutionizing health care.
This report provides:
An overview of the current landscape for molecular diagnostics
Explains the key technologies that are driving the molecular revolution
Illustrates the power of molecular diagnostics with some specific
examples
Notes some challenges that have the potential to influence progress in
the future.
Introduction
8 Making Diagnostics Matter Making Diagnostics Matter
Molecular In The News
Long-Term Reduction in Peripheral Blood HIV Type 1 Reservoirs Following
Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation
Continued clinical breakthroughs using molecular technologies
Thermo Fisher Scientific Acquires Life
Technologies in $13.6B Deal
Deals in molecular continue
Supreme Court Rule Isolated Human Genes
Cannot Be Patented
Long awaited legal decisions announced
My Medical Choice: A New York Times Op-Ed by Angelina Jolie
Celebrities Weigh In
Pfizer, Collaborators Developing
NanoString ALK Test as Lower-
Cost Alternative to FISH, IHC
Companion dx gets more interesting
9 Making Diagnostics Matter Making Diagnostics Matter
Molecular diagnostics examine the molecules in the cell, i.e. the proteins, the RNA and
DNA and how they are operating within the system that we call human biology.
What Is Molecular Diagnostics?
Pathogen
RNA
Protein
DNA
Cancer Cells
Tissue
Source: DxInsights/AdvaMedDx
10 Making Diagnostics Matter Making Diagnostics Matter
Molecular is a portion of the total global in vitro diagnostics market.
Molecular and the Global IVD Market
Source: Frost and Sullivan.
The global IVD market was $45.6B in 2012.
Total IVD market expected to grow at about
7%
Molecular market expected to grow at about
12%
Growth fueled by infectious disease and
oncology testing, and markets in new
geographies
Global In Vitro Diagnostics Market
Molecular
Rest of IVD
11 Making Diagnostics Matter Making Diagnostics Matter
With its start as a classic life science tool, polymerase chain reaction (PCR) licenses and
products topped a billion dollars in the 2000s, and the transition to the core lab is just
beginning.
Molecular Technology Evolution
Source: DxInsights/AdvaMedDx
2010s 2000s 1990s 1980s
1985 Kary Mullis
invents PCR
1998 First PCR-based
tests for HIV viral loads available in labs
Note: Adapted from Health Advances AACC presentation 2011 Source: Washington G2 reports, Health Advances analysis, Roche company data.
2011+ High-volume
infectious disease tests on automated PCR-based platforms begin to enter core lab
1991 Roche acquires
PCR from Cetus
$0 clinical revenue
2007+ <$1B clinical
revenue from licenses and products
PCR Climb To Adoption
12 Making Diagnostics Matter Making Diagnostics Matter
The Polymerase Chain Reaction (PCR) is one of many techniques used to isolate and
amplify a specific segment of DNA.
Molecular Technology Example
Source: DxInsights/AdvaMedDx
1 2 3
Amplification Cycles
Purified DNA Primers choose DNA segment of interest, PCR amplifies
sample in cycles
13 Making Diagnostics Matter Making Diagnostics Matter
A person with cystic fibrosis has a deletion of three nucleotides in their genetic sequence,
which results in the deletion of an amino acid. This manifests in the classic CF symptoms.
Classic Molecular Diagnostics
Normal Person CFTR Sequence
Person with
Cystic Fibrosis
ΔF508 CFTR
Sequence
Ile
506
Phe
508
Val
510
Deleted in ΔF508
ATC ATC TTT GGT GTT
Ile Gly
Nucleotide:
Amino acid:
Ile
506
Val
ATC ATT GGT GTT
Ile Gly
Nucleotide:
Amino acid:
Source: DxInsights/AdvaMedDx
Genetic Comparison in Cystic Fibrosis
14 Making Diagnostics Matter Making Diagnostics Matter
Diagnostics can help clinicians optimally manage patients through the continuum of care.
Comprehensive Role of Diagnostics
Source: DxInsights/AdvaMedDx
Description Diagnostic tests to complement traditional risk factors
Applied to high-risk patients to identify disease early
Used for definitive diagnosis and general typing
Assess severity and/or risk of recurrence
Inform adjuvant therapy decision
Used to predict efficacy or safety response to specific treatments
Recurrence monitoring
Monitoring for treatment efficacy
Clinical Implications
Implement wellness programs proactively
Nip disease in the bud with early treatment
Refer to the appropriate
specialist
Determine whether treatment is necessary
Do not waste unproductive therapy
Control disease progression with changes in treatment
Monitoring Therapy Selection
Staging and Prognosis
Diagnosis Screening Risk
Assessment
15 Making Diagnostics Matter Making Diagnostics Matter
There are hundreds of examples of molecular diagnostics across this continuum.
Molecular Diagnostic Examples
Source: DxInsights/AdvaMedDx
Description Diagnostic tests to complement traditional risk factors
Applied to high-risk patients to identify disease early
Used for definitive diagnosis and general typing
Assess severity and/or risk of recurrence
Inform adjuvant treatment decision
Used to predict efficacy or safety response to specific treatments
Recurrence monitoring
Monitoring for treatment efficacy
Molecular Diagnostic Example
CF carrier testing
BRCA1 testing
MRSA
HPV
TB
CT/NG
OncoType Dx
MammaPrint
BRAF
KRAS
Her2
BCR-ABL
HIV viral load
Monitoring Therapy Selection
Staging and Prognosis
Diagnosis Screening Risk
Assessment
16 Making Diagnostics Matter Making Diagnostics Matter
Companies playing in the molecular diagnostics space are varied; and collaboration and
M&A is vibrant.
Example Companies in Molecular Diagnostics
Note: Example companies only
Source: DxInsights/AdvaMedDx
17 Making Diagnostics Matter Making Diagnostics Matter
The Future Of Molecular Diagnostics
Excitement about the future of this field must be tempered by recognition of the challenges
of continuing innovation and timely patient access.
Source: DxInsights/AdvaMedDx
What is the minimal clinical evidence needed for adoption and what
investment is required?
How do regulatory bodies stay current and develop rules that makes sense
for all stakeholders?
What can we patent and what can we not?
How do we capture, store and analyze the tremendous amount of
diagnostic data?
When will our evolving reimbursement system stop evolving?
How do we address the ethical and privacy issues around some of this
diagnostic data?
IP
Clinical Evidence
IT
Regulatory
Reimbursement
Ethical
Considerations
18 Making Diagnostics Matter Making Diagnostics Matter
The Essentials of Diagnostics: Introduction to Molecular Diagnostics Read The Report
19 Making Diagnostics Matter Making Diagnostics Matter
Q&A and For More Information
www.dxinsights.org
Kristin Pothier
Partner, Health Advances;
Founder, DxInsights
www.advameddx.org
Andrew Fish
Executive Director,
AdvaMedDx